Proton pump inhibitors: Uncommon adverse effects

Australian Family Physician

Volumn 40, Issue 9, 2011, Pages 705-708

  Oh, Stephen ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Gastrointestinal disease; Proton pump inhibitors adverse effects; Therapeutics

Indexed keywords

PROTON PUMP INHIBITOR;

ARTICLE; AUSTRALIA; GASTROINTESTINAL DISEASE; HUMAN;

AUSTRALIA; GASTROINTESTINAL DISEASES; HUMANS; PROTON PUMP INHIBITORS;

EID: 80053503865     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Therapeutic Goods Administration. Medicines safety update. Available at www.tga.gov.au/hp/msu-2011-03.htm [Accessed 16 May 2011].
2. Commonwealth of Australia. Drug Utilisation Sub-Committee (DUSC) database. September 2009. Available at www.australianprescriber.com/magazine/32/6/artid/1063 [Accessed 16 may 2011].
3. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710.
4. Tack J, Talley NJ. Rome foundation diagnostic algorithms - gastroduodenal disorders. Am J Gastroenterol 2010;105:757-63.
5. Katz MH. Failing the acid test. Arch Intern Med 2010;170:747-8.
6. Raghunath AS, O'Morain C, McLoughlin RC. The long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005;22(Suppl 1):55-63.
7. National Prescribing Service. Proton pump inhibitors. Available at www.nps.org.au/__data/assets/pdf_file/0012/111423/Clinical_guidance_final_PPI.pdf [Accessed 16 May 2011].
8. Gastroenterological Society of Australia. Gastro-oesophageal reflux disease in adults. 2008. Available at www.gesa.org.au/pdf/RefluxDisease4Ed08.pdf [Accessed 16 May 2011].
9. Reimer C, Søndergaard B, Hilstead L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80-7.
10. Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptoms development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010;105:1531-7.
11. McColl KE, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology 2009;137:20-39.
12. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev 2008;66:103-8.
13. Y ang YX, Lewis JD, Epstein S, Metz DC. Longterm proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53.
14. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosisrelated fractures. CMAJ 2008;179:319-26.
15. Talley NJ, Jung HK, Jiang X, Locke GR. Is there an increased risk of hip fracture in patients on longterm PPI therapy? Nat Clin Pract Gastroenterol Hepatol 2007;4:420-1.
16. Medical Observer. TGA to consider upgrading warnings on PPIs after fracture concerns. July 2010. Available at www.medicalobserver.com.au/news/tga-to-consider-upgrading-warning-on-ppisafter-fracture-concerns [Accessed 16 May 2011].
17. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine. Gut 1996;39:54-9.
18. Leonard J, Marshall JK, Moayyedi Pl. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56.
19. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90.
20. Laheij RJ, Miriam C, Sturkenboom JM, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-60.
21. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167:950-5.
22. Roughead EE, Ramsay EN, Pratt NL, et al. Protonpump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust 2009;190:114-6.
23. Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology 2006;11:381-5.
24. Ray S, Delaney M, Muller AF. Proton pump inhibitors and acute interstitial nephritis. BMJ 2010;341:4412.
25. Sierra F, Suarez M, Rey M, Vela MF. Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007;26:545-53.
26. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. Q J Med 2010;103:387-95.
27. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011;27:180-5.
28. Allen RH, Seetharam B, Podell E, Alpers DH. Effect of proteolytic enzymes on the binding of cobalamin to R protein and intrinsic factor. In vitro evidence that a failure to partially degrade R protein is responsible for cobalamin malabsorption in pancreatic insufficiency. J Clin Invest 1978;61:47-54.
29. Sagar M, Kanczewska L, Ljungdahl A, et al. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol 1999;13:453-8.
30. Schenk BE, Ukipers EJ, Jlinkenberg-Knol EC, et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. Aliment Pharmacol 1999;13:1343-6.
31. Yeomans ND, Dent J. Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid suppression? Aliment Pharmacol Ther 2000;14:267-71.
32. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-8.
33. Jalving M, Koornstra JJ, Götz JM, et al. Highgrade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol 2003;15:1229-33.
34. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omaprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7.
35. Bhatt DL. Cryer BL. Constant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17.
36. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010;8:810-23.
37. Bour B, Staub J, Chousterman M, et al. Longterm treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 2005;21:805-12.
38. Janssen W, Meier E, Gatz G, et al. Effects of pantoprazole 20mg in mild gastroesophageal reflux disease: Once-daily treatment in the acute phases, and comparison of on-demand versus continuous treatment in long term. Curr Ther Res Clin Exp 2005;66:345-63.
39. National Prescribing Service. News 46. Proton pump inhibitors: step down to symptom control. May 2009. Available at www.nps.org.au/__data/assets/pdf_file/0016/23821/ news46.pdf [Accessed 16 May 2011].
40. Drugs for dyspepsia, reflux and peptic ulcers. In: Australian Medicines Handbook. Adelaide: Australian Medicines Handbook, 2010.